High-Value Federal Grants ($5M+) — June 23, 2026

Analogic Corp secured a firm-fixed-price delivery order from TSA for full-sized CT systems, with a potential value of $499.7 million through 2033. This competitive win under full-and-open competition confirms Analogic's moat in advanced airport security detection technology.

Leidos' cost-plus-fixed-fee delivery order with NIH/NCI for health R&D services ends in August 2024. The $4.3 million in remaining options and potential follow-on awards represent a near-term catalyst for revenue continuity.

Despite a $141.3 million ceiling, only $2.8 million has been outlayed on this 7.5-year firm-fixed-price biotech R&D contract. The company is a small, foreign-owned, self-certified small disadvantaged business, raising concerns about scalability and milestone-based revenue recognition.

START2 GROUP, INC.'s $141.3M BARDA contract has high execution risk due to only $2.8M outlayed (2% of total), a 7.5-year performance period, and the company's small, foreign-owned status. Milestone-based payments may delay revenue recognition.

Analogic Corp's $138.3M TSA contract represents a significant revenue concentration for the company, with annual estimated revenue of $12.6M from this single order. Any protest or budget cut could materially impact Analogic's top line.

Leidos Biomedical Research Inc.'s $121.5M NIH contract expires August 2024. If NIH budget allocations for NIAID VRC research are reduced or the contract is not renewed, Leidos loses ~$30.4M in annual revenue from this award.

Analogic Corp's $138.3M TSA CT system order has a potential value of $499.7M including all options through 2033. Exercise of options would provide multi-year revenue growth and signal sustained TSA investment in advanced screening technology.

START2 GROUP, INC.'s $141.3M BARDA contract for biotech R&D aligns with sustained HHS biodefense spending. If the company successfully executes milestones, it could unlock the remaining $138.5M in outlayed funding, representing significant upside for this small business.

Leidos Biomedical Research Inc.'s expiring NIH contract creates a re-compete opportunity. As a large, established contractor with a cost-plus structure, Leidos is well-positioned to win a follow-on award, potentially expanding scope or value.

Two of three contracts (Analogic Corp's TSA CT systems and START2 GROUP's BARDA biotech R&D) involve advanced technology deployment for civilian agencies, totaling $279.6M. These contracts have performance periods extending to 2031-2033, indicating sustained civilian budget commitment to modernization.

Two contracts (START2 GROUP $141.3M BARDA and Leidos $121.5M NIH) are in health R&D, totaling $262.8M or 65.5% of aggregate value. Both are tied to biodefense and vaccine research, which historically receive bipartisan support.

{"entity"=>"Analogic Corp", "reason"=>"The $138.3M TSA CT system order is a high-conviction bullish signal with long-term revenue visibility. Option exercises and competitor activity will determine upside.", "trigger"=>"TSA budget announcement for FY2027; Option exercise for additional CT systems; Competitor protest filing"}

{"entity"=>"START2 GROUP, INC.", "reason"=>"The $141.3M BARDA contract has high execution risk with only $2.8M outlayed. Milestone progress and revenue recognition are critical to monitor.", "trigger"=>"Quarterly outlayed amount increase; Company financial filings; BARDA program milestone announcements"}

{"entity"=>"Leidos Holdings, Inc.", "reason"=>"The $121.5M NIH contract expires August 2024. A follow-on award or renewal is a near-term catalyst for revenue continuity.", "trigger"=>"NIH solicitation for NIAID VRC research services; Contract modification or extension announcement; August 2024 expiration"}